March 26, 2025, Brussels, Belgium
The European Alliance for Personalised Medicine (EAPM) is pleased to share the final press release from the EU-funded CAN.HEAL project, marking a significant milestone in the mission to deliver precision cancer care across Europe.
As a key partner in the CAN.HEAL consortium, EAPM has contributed to shaping policy frameworks and stakeholder engagement around the implementation of innovative tools in oncology and public health genomics. The project’s closing conference, taking place on Thursday, 27 March 2025, will spotlight five validated, ready-to-deploy solutions developed through extensive cross-sector collaboration.
The showcased breakthroughs span:
- Standardised implementation of liquid biopsy technologies
- Improved genetic screening for pediatric cancer predisposition
- Polygenic risk models to support targeted prevention
- Integration of molecular tumour boards into standard care
- Equity-based frameworks for inclusive genomic research and healthcare delivery
These outcomes reflect CAN.HEAL’s commitment to bridging the gap between scientific innovation and equitable health system adoption—fully aligned with EAPM’s long-standing advocacy for patient-centred, data-driven personalised medicine.
Read the full press release.
EAPM encourages all stakeholders in health policy, research, and clinical practice to join the discussion at the final CAN.HEAL event—either in Brussels or online—to help shape the next chapter in Europe’s fight against cancer.
Online Participation Link
For more information about CAN.HEAL visit https://canheal.eu.
Download the event agenda.
